Bayer AG entered an exclusive global collaboration with San Diego-based Kumquat Biosciences to develop and commercialize Kumquat’s KRAS G12D inhibitor, a first-in-class agent targeting a key oncogenic mutation present in various cancers including pancreatic and colorectal tumors. With FDA IND clearance secured, the deal includes upfront payments, development and commercial milestones, and tiered royalties. This strategic alliance aims to tackle the historically 'undruggable' KRAS oncogene and expand Bayer's precision oncology portfolio.